H.C. Wainwright analyst Amit Dayal has maintained their bullish stance on BHST stock, giving a Buy rating on April 6.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Amit Dayal has given his Buy rating due to a combination of factors, including BioHarvest Sciences’ accelerating revenue growth, improving margins, and a strengthened balance sheet that supports its 2026 guidance. He points to the company’s clear outlook for rising sales, narrowing adjusted EBITDA losses, and expanding gross margins as evidence that the business model is scaling and moving closer to sustained profitability.
He also highlights the strong performance of the VINIA brand, which has quickly become a leading Resveratrol offering in the U.S. with a high proportion of recurring subscription revenue, alongside promising upside from the CDMO division. In his view, recent technical milestones in producing complex plant-derived molecules, the planned launch of premium VINIA-based products in multiple health categories, and the use of AI to enhance CDMO project success collectively support continued operational momentum and justify a positive stance on the shares.
According to TipRanks, Dayal is a 3-star analyst with an average return of 1.9% and a 32.24% success rate. Dayal covers the Industrials sector, focusing on stocks such as Broadwind Energy, Joby Aviation, and Vertical Aerospace.
In another report released on April 6, Roth MKM also maintained a Buy rating on the stock with a $10.00 price target.